Option chain shows key data for CervoMed's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for CervoMed.

CervoMed (NASDAQ:CRVO) Stock, Option Chain

CervoMed

CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

People, computer, Two,Busy,Professional,Business,People,Working,In,Office,With,Computer.

Exclusives

Trading Ideas

AAPL

ACON

AMZN

AVGO

CRVO

INTC

MLGO

MSFT

MSTR

NVDA

PLTR

PSTV

QBTS

SMCI

TSLA

A look at the top 20 most-searched stocks on Benzinga Pro in March. While many had news in the month that could affect rankings, the trends could be a sign of what&#39;s to come.

EXCLUSIVE: March&#39;s 20 Most-Searched Tickers On Benzinga Pro — Where Do Tesla, Nvidia, Apple, Applovin Stock Rank?

Neurologist,Hand,Pointing,Brain,Anatomy,Human,Model,And,Brain,Disease

Analyst Color

Biotech

News

Upgrades

Health Care

Price Target

Analyst Ratings

General

CervoMed&#39;s Phase 2b study extension shows improved cognitive outcomes with neflamapimod, leading to an analyst upgrade and increased confidence in the drug.

CervoMed&#39;s Dementia Study&#39;s 16-Week Data &#39;Compelling Enough To Move From Sidelines&#39; Analyst Says

Wells Fargo

Pre-Market Outlook

Markets

INVH

This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

CervoMed Inc

Press Releases

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Clinical Trial Results Show Positive Signs For Potential New Dementia Treatment

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CervoMed to Present at the 8th International Lewy Body Dementia Conference

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Earnings

CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025

Anixa Biosciences

Atossa Therapeutics

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

C4 Therapeutics

Climb Bio

Coya Therapeutics

Elicio Therapeutics

Elutia

EXoZymes

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genelux

HilleVax

Immunic

Macrogenics

OncoCyte

Senti Biosciences

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Tenaya Therapeutics

Vor Biopharma

Vaxart

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

XBiotech

Exagen

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

D. Boral Capital

Roth MKM

Canaccord Genuity

Chardan Capital

Jones Trading

Screenshot 2024-11-26 at 7.00.24 PM

Interview

Comments

CervoMed

CervoMed (CRVO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga